Park Avenue Securities LLC Has $397,000 Stock Holdings in Qiagen (NYSE:QGEN)

Park Avenue Securities LLC increased its position in Qiagen (NYSE:QGEN) by 32.1% during the fourth quarter, Holdings Channel reports. The firm owned 8,908 shares of the company’s stock after buying an additional 2,166 shares during the quarter. Park Avenue Securities LLC’s holdings in Qiagen were worth $397,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of QGEN. American Century Companies Inc. increased its holdings in shares of Qiagen by 34.2% in the second quarter. American Century Companies Inc. now owns 31,904 shares of the company’s stock valued at $1,311,000 after purchasing an additional 8,130 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Qiagen by 57.0% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 9,723 shares of the company’s stock valued at $400,000 after purchasing an additional 3,530 shares during the period. XTX Topco Ltd acquired a new position in Qiagen in the 2nd quarter valued at $362,000. Public Sector Pension Investment Board increased its position in Qiagen by 5.9% during the 2nd quarter. Public Sector Pension Investment Board now owns 92,993 shares of the company’s stock worth $3,809,000 after buying an additional 5,185 shares during the period. Finally, Point72 DIFC Ltd lifted its holdings in shares of Qiagen by 53.7% during the second quarter. Point72 DIFC Ltd now owns 6,066 shares of the company’s stock worth $249,000 after buying an additional 2,119 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Down 0.3 %

Shares of NYSE QGEN opened at $45.70 on Friday. The company has a market cap of $10.43 billion, a price-to-earnings ratio of 117.18, a PEG ratio of 3.49 and a beta of 0.37. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.93. The stock has a 50-day moving average price of $44.60 and a two-hundred day moving average price of $44.27.

Analysts Set New Price Targets

A number of equities analysts recently commented on QGEN shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $54.00 price target (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research report on Thursday, October 17th. Morgan Stanley reissued an “equal weight” rating and set a $48.00 price target (down previously from $50.00) on shares of Qiagen in a research report on Monday, January 6th. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Qiagen currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.50.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.